Zevra Therapeutics Inc (ZVRA)
9.13
+0.16
(+1.78%)
USD |
NASDAQ |
Nov 21, 16:00
9.145
+0.02
(+0.16%)
Pre-Market: 20:00
Zevra Therapeutics Debt to Equity Ratio: 0.8443 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.8443 |
| June 30, 2024 | 1.796 |
| March 31, 2024 | 0.8808 |
| December 31, 2023 | 0.6913 |
| September 30, 2023 | 0.6503 |
| June 30, 2023 | 0.1855 |
| March 31, 2023 | 0.1809 |
| December 31, 2022 | 0.1704 |
| September 30, 2022 | 0.1365 |
| June 30, 2022 | 0.129 |
| March 31, 2022 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.0093 |
| December 31, 2020 | -1.030 |
| September 30, 2020 | -1.070 |
| June 30, 2020 | -1.082 |
| March 31, 2020 | -0.999 |
| December 31, 2019 | -1.039 |
| September 30, 2019 | -1.094 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-1.082
Minimum
Jun 2020
1.796
Maximum
Jun 2024
0.0227
Average
0.0692
Median
Debt to Equity Ratio Benchmarks
| Ionis Pharmaceuticals Inc | 1.930 |
| Vanda Pharmaceuticals Inc | 0.00 |
| BioCardia Inc | -- |
| Xeris Biopharma Holdings Inc | -8.166 |
| Instil Bio Inc | -- |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 191.55M |
| Total Liabilities (Quarterly) | 121.78M |
| Shareholders Equity (Quarterly) | 69.77M |
| Current Ratio | 2.884 |
| Net Debt Paydown Yield | -2.50% |